

ALCMI RESISTANCE TRIAL PROGRAM

A Proven, Fully Managed Solution for IND-Exempt Biomarker Trials



Find New Drug Targets

Your KRAS, ALK, EGFR, RET, MET, or ROS1 inhibitor is delivering meaningful benefit but resistance is coming for people on these treatments. Understanding how and why tumors escape your therapy is both scientifically critical and increasingly important.

ALCMI can design, launch, and manage that study for you.

If you have a marketed TKI and an unmet need for resistance data, we're ready to build your trial.

What We Can Do For You

- Protocol design & IRB submission
- ClinicalTrials.gov registration & management
- Remote, decentralized patient enrollment (nationwide)
- Blood kitting, remote phlebotomy logistics
- Biospecimen collection & banking
- Centralized data management
- Medical writing & publication/conference support

We have been running Resistance Trials for nearly two decades. Here are three worth your attention:

SPACEWALK

ALK+ TKI Resistance
Published, JTO C&RR

ENIGMA

ALK+ Resistance
Results Pending

SPARK

KRAS Inhibitor Resistance
To Be Presented at WCLC 2026

Contact Us

- 📞 (248) 444-2181
- ✉️ rerwin@alcmi.org
- 🌐 www.alcmi.org

